Parresia logo
Rechercher
Menu
Accueil Tous les numéros Numéro 263 (Juin 2013) Actual. Odonto-Stomatol., 263 (2013) 19-31 Références
Open Access
Numéro
Actual. Odonto-Stomatol.
Numéro 263, Juin 2013
Odontologie hospitalière
Page(s) 19 - 31
DOI https://doi.org/10.1051/aos/2013304
Publié en ligne 21 juin 2013
  1. Haute Autorite de Sante. Recommandations professionnelles. Polyarthrite rhumatoide. Prise en charge en phase d’etat. 2007. [Google Scholar]
  2. Teillaud JL. Qu’est ce qu’une biotherapie ? L’exemple des anticorps monoclonaux. Presse Med. 2009;38:825-31. [CrossRef] [PubMed] [Google Scholar]
  3. Haute autorite de Sante. Polyarthrite rhumatoide. Syntheses des recommandations. Septembre 2007. [Google Scholar]
  4. Fautrel B, Pham T, Mouterde G, Le Loet X, Goupille P, Guillemin F, Ravaud P, Cantagrel A, Dougados M, Puechal X, Sibilia J, Soubrier M, Mariette X, Combe B. Club Rhumatismes et Inflammation; Societe Francaise de Rhumatologie. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine. 2007;74(6):627-37. [CrossRef] [PubMed] [Google Scholar]
  5. Hession MT, Gottlieb AB. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. J Dermatolog Treat. 2011;22(2):90-101. [CrossRef] [PubMed] [Google Scholar]
  6. Marchal L, D’Haens G, van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease : a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-54. [CrossRef] [PubMed] [Google Scholar]
  7. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83. [CrossRef] [PubMed] [Google Scholar]
  8. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730-6. [CrossRef] [PubMed] [Google Scholar]
  9. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 2008;12:1738-44. [CrossRef] [PubMed] [Google Scholar]
  10. Yang Z, Wu K, Fan D. Meta-analysis: preoperative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010;31:486-92. [CrossRef] [PubMed] [Google Scholar]
  11. Van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2009;68(7):1153-8. [CrossRef] [PubMed] [Google Scholar]
  12. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956-62. [CrossRef] [PubMed] [Google Scholar]
  13. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51:1202-7. [CrossRef] [PubMed] [Google Scholar]
  14. Coquet-Renier B, Berdah SV, Grimaud JC, et al. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a casematched study. Surg Endosc 2010;24:1866-71. [CrossRef] [PubMed] [Google Scholar]
  15. Regadas FS, Pinto RA, Murad-Regadas SM, et al. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal. Colorectal Dis. 2011;13(5):555-60. [CrossRef] [PubMed] [Google Scholar]
  16. Hirano Y, Kojima T, Kanavama Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:495-500. [CrossRef] [PubMed] [Google Scholar]
  17. Kawakami K, Ikari K, Kawamura K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications ? Rheumatology (Oxford) 2010;49:341-7. [CrossRef] [PubMed] [Google Scholar]
  18. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5. [PubMed] [Google Scholar]
  19. Wendling D, Balblanc JC, Brousse A, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005;64:1378-9. [CrossRef] [PubMed] [Google Scholar]
  20. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7. [CrossRef] [PubMed] [Google Scholar]
  21. Matthews JLK, Martin L, Hu R. Postoperative complications in rheumatoid arthritis patients on anti-TNF therapies undergoing orthopaedic procedures. Ann Rheum Dis 2006;65(Suppl.II):331(Abs FRI0147). [Google Scholar]
  22. Salliot C, Gossec L, Ruyssen-Wiltrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice : a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46:327-34. [CrossRef] [PubMed] [Google Scholar]
  23. Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6. [PubMed] [Google Scholar]
  24. Gilson M, Gossec M, Mariette X, et al. Risk factors of total joint arthroplasty infection in patients receiving TNFα blockers : a case-control study. Arthritis Res Ther. 2010;12(4):R145. [CrossRef] [PubMed] [Google Scholar]
  25. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85. [CrossRef] [PubMed] [Google Scholar]
  26. Club Rhumatismes et Inflammation (CRI). Anti-TNF alpha et suivi de la tolerance. Fiches pratiques. Decembre 2006. [Google Scholar]
  27. AFSSAPS. Recommandations nationales. Prevention et prise en charge des tuberculoses survenant sous anti-TNF alpha. Juillet 2005. [Google Scholar]
  28. Societe francaise de rhumatologie. Traitements anti-TNFα et suivi de la tolerance. Conduite a tenir en cas de chirurgie et soins dentaires. 2008. [Google Scholar]
  29. Nishida K, Hashizume K, Kadota Y, et al. Time-concentration profile of serum etanercept in Japanese patients with rheumatoid arthritis after treatment discontinuation before orthopedic surgery. Mod Rheumatol. 2010;20(6):637-9. [CrossRef] [PubMed] [Google Scholar]
  30. Martin C, Bantz P, Thomachot L. Antibioprophylaxie en chirurgie. In Bergogne-Berezin E, Dellamonica P. Antibiotherapie en pratique clinique. Abrégés Masson, 2ème édition, Paris 1999. [Google Scholar]
  31. DenBroeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689-95. [PubMed] [Google Scholar]
  32. Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63. [CrossRef] [PubMed] [Google Scholar]
  33. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49(11):2217-9. [CrossRef] [PubMed] [Google Scholar]
  34. Ortiz P, Bissada NF, Palomo L, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 2009;80:535-40. [CrossRef] [PubMed] [Google Scholar]
  35. Pers JO, Saraux A, Pierre R, et al. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol 2008;79:1645-51. [CrossRef] [PubMed] [Google Scholar]
  36. Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry : a review and practice recommendations. JADA 2000;131:366-74. [Google Scholar]
  37. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-7; quiz 1176. [CrossRef] [PubMed] [Google Scholar]